BSE Live
Jan 21, 16:01Prev. Close
764.85
Open Price
764.00
Bid Price (Qty.)
758.00 (1)
Offer Price (Qty.)
800.00 (5)
NSE Live
Jan 21, 15:59Prev. Close
765.15
Open Price
762.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
761.80 (13)
| Balance Sheet of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 37.70 | 37.70 | 37.70 | 37.70 | 37.70 | |
| Total Share Capital | 37.70 | 37.70 | 37.70 | 37.70 | 37.70 | |
| Reserves and Surplus | 795.86 | 591.99 | 422.06 | 323.16 | 238.51 | |
| Total Reserves and Surplus | 795.86 | 591.99 | 422.06 | 323.16 | 238.51 | |
| Total Shareholders Funds | 833.57 | 629.70 | 459.76 | 360.86 | 276.21 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 18.80 | 52.22 | 70.53 | 94.86 | 128.48 | |
| Deferred Tax Liabilities [Net] | 31.43 | 22.72 | 13.90 | 9.53 | 5.37 | |
| Other Long Term Liabilities | 12.84 | 12.70 | 12.76 | 12.29 | 11.84 | |
| Long Term Provisions | 9.36 | 6.68 | 6.06 | 5.39 | 5.10 | |
| Total Non-Current Liabilities | 72.44 | 94.32 | 103.25 | 122.07 | 150.80 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 149.81 | 25.42 | 70.11 | 139.46 | 146.28 | |
| Trade Payables | 302.38 | 281.90 | 234.25 | 181.93 | 131.75 | |
| Other Current Liabilities | 58.36 | 60.62 | 69.25 | 150.57 | 84.90 | |
| Short Term Provisions | 94.60 | 70.48 | 62.06 | 35.66 | 25.91 | |
| Total Current Liabilities | 605.15 | 438.43 | 435.67 | 507.62 | 388.84 | |
| Total Capital And Liabilities | 1,511.16 | 1,162.45 | 998.68 | 990.55 | 815.85 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 488.68 | 396.96 | 344.22 | 267.82 | 271.99 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 83.14 | 20.67 | 32.26 | 58.24 | 26.50 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 571.82 | 417.63 | 376.48 | 326.06 | 298.49 | |
| Non-Current Investments | 33.33 | 33.33 | 3.35 | 3.35 | 3.35 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 65.03 | 41.64 | 35.88 | 34.99 | 6.54 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 670.18 | 492.60 | 415.72 | 364.40 | 308.39 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 382.48 | 310.78 | 266.83 | 258.74 | 219.23 | |
| Trade Receivables | 337.94 | 260.56 | 232.38 | 186.83 | 201.97 | |
| Cash And Cash Equivalents | 4.41 | 5.34 | 4.25 | 25.72 | 1.29 | |
| Short Term Loans And Advances | 116.15 | 93.17 | 79.50 | 154.85 | 84.97 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 840.98 | 669.85 | 582.97 | 626.15 | 507.46 | |
| Total Assets | 1,511.16 | 1,162.45 | 998.68 | 990.55 | 815.85 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 152.50 | 68.60 | 51.70 | 51.17 | 120.29 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 204.97 | 176.49 | 155.42 | 186.31 | 178.82 | |
| Stores, Spares And Loose Tools | 3.76 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 3.76 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 103.25 | 69.44 | 55.39 | 38.95 | 24.46 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 808.45 | 750.17 | 465.02 | 467.96 | 360.48 | |
| Other Earnings | 19.97 | 21.79 | 15.22 | 11.60 | 0.47 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 33.33 | 33.33 | 3.35 | 3.35 | 3.35 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
17.11.2025
Alembic Pharma shares gain 2% on USFDA nod for Diltiazem Hydrochloride tablets
17.11.2025
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct